Advertisement
Canada markets close in 2 hours 52 minutes
  • S&P/TSX

    21,855.45
    -18.27 (-0.08%)
     
  • S&P 500

    5,033.54
    -38.09 (-0.75%)
     
  • DOW

    38,001.41
    -459.51 (-1.19%)
     
  • CAD/USD

    0.7311
    +0.0014 (+0.19%)
     
  • CRUDE OIL

    82.47
    -0.34 (-0.41%)
     
  • Bitcoin CAD

    88,335.52
    -298.39 (-0.34%)
     
  • CMC Crypto 200

    1,391.82
    +9.25 (+0.67%)
     
  • GOLD FUTURES

    2,340.40
    +2.00 (+0.09%)
     
  • RUSSELL 2000

    1,973.02
    -22.41 (-1.12%)
     
  • 10-Yr Bond

    4.6940
    +0.0420 (+0.90%)
     
  • NASDAQ

    15,546.04
    -166.71 (-1.06%)
     
  • VOLATILITY

    16.45
    +0.48 (+3.01%)
     
  • FTSE

    8,078.86
    +38.48 (+0.48%)
     
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     
  • CAD/EUR

    0.6809
    -0.0010 (-0.15%)
     

Why Pfizer Looks Better Than Moderna as a Long-Term Buy

Why Pfizer Looks Better Than Moderna as a Long-Term Buy

For a stock to be a strong long-term buy, investors need to have confidence that its business will be able to grow indefinitely. Both Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE) are examples of companies that continue to thrive today due to the pandemic with their highly successful COVID-19 vaccines generating billions in sales for their respective companies. COVID-19 revenue has resulted in surging revenue for Pfizer.